GLP-1 receptor agonists have established compelling evidence for the commercial value of multi-indication drug development beyond obesity. Conventional paradigms for drug development must shift in order to adapt to multi...
Press releases
-
BARDA reselects ICON as preferred partner to help strengthen US emergency preparedness and response
To help strengthen US emergency preparedness and response. ICON continues as part of BARDA’s exclusive Medical Countermeasures Clinical Studies Network.
-
ICON wins Best CRO at the Vaccine Industry Excellence Awards
This marks the third time ICON plc has won the award for excellence in vaccine research. The company has been named as a finalist every year since 2011.
-
ICON launches Accellacare a global clinical research network focused on increasing patient recruitment with a patient centric approach
Enhances ICON’s ability to offer customers integrated solutions of patient assessments at site and in-home for decentralised trials.
-
Forbes names ICON in list of Best Employers in America for Women
ICON recognised as top employer for women in anonymous survey of 75,000 employees.
-
ICON shareholders vote in favour of all resolutions at its Annual General Meeting
Dublin, Ireland, July 22, 2020
-
ICON reports first quarter 2020 results
Reported revenue of $715.1 million representing a 6.0% YoY increase or 6.5% on a constant currency basis. Net business wins of $867 million; a book to bill of 1.21.
-
ICON wins multiple categories in 2020 CRO Leadership Awards third year in a row
ICON recognised for specialised services offering across product development lifecycle, winning five awards overall.
-
ICON signs new service agreement with Pfizer
Agreement builds on the companies' existing relationship, under which ICON provides global expertise in the planning, execution, management and conduct of clinical trials.
-
ICON launches the Coronavirus Observatory
The Coronavirus Observatory applies powerful AI analysis and data visualisation to COVID-19 news and social media, providing updates on the latest vaccine trials.
-
ICON acquires MedPass International
Acquisition expands ICON’s global Medical Device and Diagnostic Research Services
